-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Revelation Biosciences Inc. Announces Conference Call to Provide a Corporate Update
Revelation Biosciences Inc. Announces Conference Call to Provide a Corporate Update
-CLEAR Study enrollment ongoing top-line data expected 2H 2022-
-Diagnostic partnering discussions ongoing-
SAN DIEGO, April 06, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, today announced that it will host investor conference call on April 7, 2022 at 4:30 p.m. Eastern Time. The conference call can be accessed by dialing (877) 815-0146 for domestic callers and (631) 625-3219 for international callers. Please provide the operator with the passcode 1166664 to join the conference call. An archive of the conference call will be available on Revelation's website for 30 days following the call.
About Revelation Biosciences Inc.
Revelation Biosciences Inc. is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has multiple product candidates in development. REVTx-99b, the lead therapeutic candidate, is being developed for allergic rhinitis and chronic nasal congestion. REVTx-99b is currently being evaluated as a treatment for allergic rhinitis in a phase 1b CLEAR study. Topline results are expected in the second half of 2022. REVDx-501, a rapid home use diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation. Revelation has engaged MedWorld Advisors to facilitate partnering of the REVDx-501 asset. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity.
For more information on Revelation, please visit .
Company Contacts
Sandra Vedrick
Vice President, Investor Relations & Human Resources
Revelation Biosciences Inc.
Email: svedrick@revbiosciences.com
and
Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com
-CLEAR Study enrollment ongoing top-line data expected 2H 2022-
-Diagnostic partnering discussions ongoing-
-明确的研究登记正在进行的顶线数据预计2022年下半年-
-诊断合作伙伴关系讨论正在进行-
SAN DIEGO, April 06, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, today announced that it will host investor conference call on April 7, 2022 at 4:30 p.m. Eastern Time. The conference call can be accessed by dialing (877) 815-0146 for domestic callers and (631) 625-3219 for international callers. Please provide the operator with the passcode 1166664 to join the conference call. An archive of the conference call will be available on Revelation's website for 30 days following the call.
圣迭戈,2022年4月6日(环球通讯社)--专注于开发基于免疫学的预防和治疗疾病的疗法的临床期生命科学公司启示录生物科学公司(纳斯达克:REVB)(以下简称“公司”或“启示录”)今天宣布,它将于2022年4月7日下午4:30主持投资者电话会议。东部时间。国内呼叫者拨打(877)815-0146,国际呼叫者拨打(631)625-3219即可收听电话会议。请向接线员提供加入电话会议的密码1166664。电话会议的档案将在电话会议结束后30天内在启示录的网站上提供。
About Revelation Biosciences Inc.
关于启迪生物科学公司。
Revelation Biosciences Inc. is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has multiple product candidates in development. REVTx-99b, the lead therapeutic candidate, is being developed for allergic rhinitis and chronic nasal congestion. REVTx-99b is currently being evaluated as a treatment for allergic rhinitis in a phase 1b CLEAR study. Topline results are expected in the second half of 2022. REVDx-501, a rapid home use diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation. Revelation has engaged MedWorld Advisors to facilitate partnering of the REVDx-501 asset. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity.
启迪生物科学公司是一家临床阶段的生命科学公司,专注于开发基于免疫学的预防和治疗疾病的疗法。启示录有多个候选产品正在开发中。REVTx-99b是治疗过敏性鼻炎和慢性鼻塞的主要候选药物。REVTx-99b目前正在1b期Clear研究中作为治疗过敏性鼻炎的药物进行评估。预计2022年下半年将公布TOPLINE结果。REVDx-501,一种家庭使用的快速诊断,可用于检测任何呼吸道病毒感染,无论病毒类型或毒株,而不需要专门的仪器。启示录已聘请MedWorld Advisors促进REVDx-501资产的合作。REVTx-200是一种鼻腔免疫调节剂辅助剂,可与肌肉接种结合使用,以获得更完全的免疫。
For more information on Revelation, please visit .
有关《启示录》的更多信息,请访问。
Company Contacts
公司联系人
Sandra Vedrick
Vice President, Investor Relations & Human Resources
Revelation Biosciences Inc.
Email: svedrick@revbiosciences.com
桑德拉·韦德里克
投资者关系和人力资源部副总裁
启示录生物科学公司。
电子邮件:svedrick@revbiosciences.com
and
和
Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com
切斯特·齐格蒙特,III
首席财务官
启示录生物科学公司。
电子邮件:czygmont@revbiosciences.com
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧